https://www.selleckchem.com/pr....oducts/PD-173074.htm
Most high‐income countries are aggressively engaged in the collection and research evaluation of convalescent plasma as a specific passive immunotherapy for treatment of COVID‐19. Preliminary clinical data fully support such initiatives. Outbreaks of COVID‐19 are now dramatically affecting LMIC, which have restricted capability for ensuring organized and controlled collection of safe blood and plasma collection due to fragmented blood systems with limited oversight, infrastructure, equipment, and trained personnel. Nevertheless, there
Like
Comment
Share
